BACKGROUND

Originated from translational/prognosis studies in ccRCC (clear cell renal cell carcinoma)

Multiple targets (3) designed to prevent « tumor escape »

Initial POC/xenograft model in ccRCC

Pathway key to Cancer Stem Cells proliferation/differentiation

HER2 positive Breast Cancer identified as second best indication (on-going POC)

HOW IT WORKS

Researchers showed that cytokines CXCL1,7 and 8 and CXCL receptors (CXCR1 and CXCR2) are overexpressed in RCC cells and are markers of bad prognosis. The secretion of these CXCL and the presence of their receptors on tumor cells generate autocrine proliferations loops via activation of the ERK/MAP Kinase signaling pathway.

2 tri-specific monoclonal antibodies able to inhibit simultaneously the CXCL1, 7 and 8 have been selected among 3840 hybridomas. No further mAb optimization undertaken at this lead stage.

Significant recent literature underlying the key function of the CVXL/CVXL8/CVXR pathway in the regulation of CSC particularly in HER2 Breast Cancer

HIGHLIGHTS OF P0TENTIAL BENEFITS

Development Status

We are looking for a company interested to further develop this concept

We also plan to validate the CXCL antibodies for breast cancer treatment

APPLICATIONS

Second line immunotherapy for renal cell carcinoma

HER2+ breast cancer (CSC)

Companion test for anti-CXCL therapy